Prostate cancer immune study pulled before start
NCT ID NCT03274778
First seen Nov 18, 2025 · Last updated May 13, 2026 · Updated 25 times
Summary
This study planned to give men with prostate cancer the drug ruxolitinib for 28 days before their prostate removal surgery. Researchers wanted to see how the drug changes immune cells in the tumor and blood. However, the study was withdrawn before any participants were enrolled, so no results are available.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Istituto Oncologico della Svizzera Italiana (IOSI)
Bellinzona, 6500, Switzerland
Conditions
Explore the condition pages connected to this study.